Advising

Dr. Parikh provides consulting to companies ranging from early-stage startups to Fortune 500 organizations, including health insurers, health systems, biopharma, and digital health companies. He provides high-level clinical and strategic guidance, input on AI training and validation, clinical interpretation of model outcomes, and design of operational and research programs. He also advises nonprofits and guideline bodies on cancer care and advanced illness payment and delivery system reform.

Machine learning

  • In silico trials: Served as clinical lead for a product that used causal artificial intelligence to simulate in silico effectiveness of novel drug targets, subsequently commercialized by an intermediate-stage technology company

  • Radiomic biomarkers of cancer progression: Provide strategic guidance and clinical insight for an early-stage startup using AI to predict effectiveness of novel agents from routine imaging

  • Drug Discovery: Providing clinical guidance to early-stage AI company looking to establish computational models for drug discovery

 

Cancer care delivery

  • Digital Clinical Trial Solutions: Guiding later-stage startup in establishing digital solutions to streamline clinical trial enrollment and data collection

  • Right care, right time for cancer referrals: Guided an early-stage startup in establishing a tertiary care referral network for labor union and other members with cancer

  • Optimizing germline testing for cancer: Provide interpretation for a Fortune 500 biopharma company investigating underutilization of germline testing in advanced prostate cancer

  • Cancer care at home: Guiding a unicorn startup in establishing a virtual care-at-home program among patients with cancer

Advanced illness

  • Virtual palliative care: Provide strategic guidance for a Fortune 500 company building a remote palliative care program offering for seriously ill members

  • Engaging navigators in advance care planning: Provide guidance for an early-stage navigation company seeking to engage members with cancer in advance are planning

Policy and quality

  • Board of Directors, Coalition to Transform Advanced Care (C-TAC)

  • Member, National Academies Human and Organizational Factors in AI Risk Management: A Workshop

  • Leadership Consortium, National Quality Forum

  • Publications Committee, American College of Physicians

  • Medicare Evidence Development & Coverage Advisory Committee

  • Utilization Measurement Advisory Panel (UMAP), National Committee for Quality Assurance

  • Board of Directors, American Cancer Society - Greater Philadelphia Region